focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Chariot expects gas in Morocco; Redx wants CFO in US

Tue, 02nd Mar 2021 21:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

All Active Asset Capital Ltd - London-based firm seeking investment opportunities in the technology, software and artificial intelligence space - Exercises first tranche of the option agreement with AAQUA BV, and has acquired 6,000 new AAQUA shares. Under the terms of the option, AAA can subscribe for up to 125,000 new AAQUA ordinary shares at EUR1,000 per share, being a total cost of EUR125 million if fully exercised. AAA paid a EUR1 million fee for the grant of the option to AAQUA in December 2020. The grant fee is offset against the initial exercise cost payable by AAA; and so AAA's incremental cost of this initial exercise is EUR5 million.

----------

Redx Pharma PLC - Macclesfield, England-based treatments for cancer and fibrotic disease - Starts search for US-based chief financial officer. Notes James Mead will continue in his role as CFO until a new appointment has been made at which point Mead will assume the role of chief operating officer. Chair Iain Ross adds: "In conjunction with these changes, Mead will step down from the board with immediate effect and will cease to be a director of the company. Going forward, the board will therefore consist of five non-executive directors and one executive director, the CEO."

----------

Verici Dx PLC - clinical diagnostics developer for organ transplant - Partners Lorenzo Gallon, at Northwestern University Feinberg School of Medicine; Milagros Samaniego, at Henry Ford Health System and Daniel Maluf, at the University of Maryland, Baltimore to collaborate on company's clinical trial surrounding its two lead products, ClaravaTM and TutevaTM, and longer term, the validation of the fibrosis test. "The study uses next generation sequencing in the Verici Dx laboratory to create transcriptomic profiles to validate performance characteristics of the lead Verici Dx immune-phenotype signature tests," company explains.

----------

Amiad Water Systems Ltd - Israel-based water treatment and filtration systems - Launches Spin Klin Nova, a disc filtration system. "This cutting-edge solution, which is the culmination of years of R&D work, is the company's most efficient product to date. It includes multiple new features that are designed to make it as adaptable as possible to the needs of the customer while increasing ease of use," company says. Spin Klin Nova is available now in Israel and will be released globally later this month.

----------

Chariot Oil & Gas Ltd - Africa focused transition energy company - Signs memorandum of understanding along with its partner the Office National des Hydrocarbures et des Mines with the Ministry of Industry, Trade & Green and Digital Economy in Morocco. The MOU relates to the ministry's support of Chariot and ONHYM's Anchois gas development project as a potential provider of significant gas to the Moroccan gas market. Chariot's acting Chief Executive Adonis Pouroulis says: "The signing of this MOU is a significant step in our efforts to access the Moroccan gas markets. With the Kingdom of Morocco's support we intend to build on the positive conversations we are already having with entities involved in the Moroccan gas market, giving us greater confidence that we will sign the necessary agreements to expedite the development of this value accretive gas project, for the benefit of the Kingdom and Chariot's investors."

----------

Hurricane Energy PLC - Surrey-based oil and gas company - Says discussions on Lancaster field forward work programme, strategy, financing and balance sheet recapitalisation are ongoing. Looking at drilling the side-track in 2022 following further planning activity during 2021; or drilling the side-track together with the previously contemplated water injection well as a combined programme in 2022. If those do not pan out, considering drilling the side-track in 2022 and the water injection well in 2023. Hurricane adds: "Proposed side-track is more complex in nature than previous wells on Lancaster due to the incorporation of an intelligent completion and the challenges of delivering the well trajectory from the side-track location."

----------

Tern PLC - internet of things-focused investor - Pleased with recent momentum of portfolio companies. Notes Device Authority Ltd, Talking Medicines Ltd and Wyld Networks Ltd have had a good start to 2021 and have "promising" pipelines of business. Chief Executive Al Sisto says: "Device Authority's IoT summit last week, funded by its partner sponsors, was a particular milestone for the company, demonstrating the depth of their relationships and the important position their KeyScaler product has in the IoT. I wholly endorse one speaker from a global software company who commented that KeyScaler is 'the glue that holds the IoT together'." Adds: "I would also like to congratulate Talking Medicines on being selected as part of Healthcare UK's 'Fast 100'. This recognises Talking Medicines' innovation and their commitment to global expansion."

----------

Mkango Resources Ltd - explorer for rare earth elements in Malawi - Completes flotation pilot plant programme for the Songwe Hill rare earths project in Malawi. The results of the flotation pilot programme will be announced in due course, and the flotation concentrate produced will be supplied to ANSTO in Australia for hydrometallurgical piloting. "Discussions in relation to sites for a rare earth separation plant are ongoing - this will process the high grade, purified mixed rare earth carbonate produced at Songwe, enriched in high value neodymium, praseodymium, dysprosium and terbium," company adds.

----------

IXICO PLC - AI data analytics company - Says Cyclerion Therapeutics Inc, a new client, to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease. For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging, diffusion MRI, resting state functional MRI and arterial spin labelling. "Whilst this contract does not change management's expectations of financial performance for the year, it adds to the company's strong order book, further increases visibility of future revenues, and reflects an increasing diversification of the company's client base," company adds.

----------

Westmount Energy Ltd - South America-focused energy investor - Notes the Stena Carron drillship is moving from the Bulletwood-1 location on the Canje block, offshore Guyana, to a new drilling location on the Stabroek block. "Westmount is not a direct participant in the Canje Joint Venture and is therefore not aware of the outcome of the Bulletwood-1 well. The company awaits confirmation and disclosure of the Bulletwood-1 drilling results by the operator or other Canje JV partners. It is the company's intention to update the market as soon as these drilling results are publicly available," company adds. Company plans drilling of the second and third wells on the Canje block, Jabillo-1 and Sapote-1, over the coming months.

----------

Bahamas Petroleum Co - Caribbean and Atlantic margin focused oil and gas company - Notes Honourable Justice Petra Hanna-Weekes allowed the company's application and ordered the applicants to post USD200,000 security for costs within 30 days, pending which the proceedings will be stayed. BPC recently added as a respondent to the application brought by environmental groups against the government of the Bahamas. BPC was entitled to request that the applicants provide security for costs.

----------

Enteq Upstream PLC - oil & gas drilling technology company based in Buckinghamshire - Launches disruptive alternative to traditional rotary steerable systems. The SABER tool is now ready for next stage field trials. "The SABER tool uses internally directed pressure differentials to steer from the drill bit face, delivering true 'at-bit' geo-steering. This mechanically simple design also removes the need for traditional pistons and pads that are susceptible to reliability issues - an approach which can create a smoother and more precise wellbore with easy to manage directional control. SABER will offer a robust, reliable, simple and cost effective directional drilling alternative to current RSS options," Enteq explains.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Signs letter of intent with Thai Airways under which the parties have agreed to amend the existing lease terms. The new terms provide for a "power by the hour" arrangement until the end of next year, with scaled back monthly lease payments thereafter, reflecting the reduced rates now seen in the market. The lease term will be extended from October 2026 to December 2029, with the company retaining a right of early termination in October 2026. Agrees with Thai lenders to amend and restate the existing loan facility agreements in respect of the Thai assets.

----------

Mobile Streams PLC - mobile content and data intelligence company headquartered in London - Says Chinese language version of Streams will launch on March 14. Streams China is aimed specifically at the Chinese market for companies that want to sell their products and services to a western audience. Also notes revenues and customer growth continue to remain ahead of internal forecasts, and monthly Streams Data revenue has now exceeded the net revenue brought in via the legacy business. Says Streams SaaS platform which generated initial customer revenues in October, now generating monthly revenue of GBP12,000, up 33% year on year. "Whilst still at a modest level, with our pipeline of product development and marketing, we expect to see significant growth in 2021, with additional higher price points to come," company adds.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more
11 May 2023 18:17

IN BRIEF: Redx reports positive preclinical data for fibrosis drug

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Announces preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor 1/2 discovery programme, as presented yesterday at the Resistant Tumour Microenvironment, Keystone Symposia, in Vancouver. Notes the data presented were from preclinical models of pancreatic ductal adenocarcinoma and triple negative breast cancer in combination with chemotherapy and immunotherapy, as current standard of care. Says RXC007, in combination with gemcitabine/Abraxane in metastatic and high-extra cellular matrix patient-derived PDAC models, was shown to increase survival compared to single agent standard of care alone. The combination of RXC007 with standard of care provided a significant increase in median survival days from date of treatment in a dose dependent manner. These new data on RXC007 complement those also presented at the meeting by collaboration partner the Garvan Institute of Medical Research on REDX10616, a close analogue of RXC007. Taken together, these data provide a strong rationale for the potential of ROCK2 inhibition in combination with standard of care as a potential treatment for cancer-associated fibrosis. Redx plans to further investigate this treatment setting with the company's next-generation ROCK2 inhibitor, RXC007. Further, at the Keystone Symposia, data were also presented from Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models. Using a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771 model resulted in a statistically significant increase in survival when compared to the control group, an effect not observed with either single agent alone.

Read more
10 May 2023 15:45

UK earnings, trading statements calendar - next 7 days

Thursday 11 May 
3i Group PLCFull Year Results
Airtel Africa PLCFull Year Results
Eurocell PLCTrading Statement
Donegal Investment Group PLCHalf Year Results
Grainger PLCHalf Year Results
Hurricane Energy PLCFull Year Results
ICG Enterprise Trust PLCFull Year Results
IQE PLCFull Year Results
ITV PLCTrading Statement
John Wood Group PLCTrading Statement
Morgan Advanced Materials PLCTrading Statement
Rolls-Royce Holdings PLCTrading Statement
S4 Capital PLCQ1 Results
TBC Bank Group PLCQ1 Results
Friday 12 May 
Allianz Technology Trust PLCQ1 Results
Balfour Beatty PLCTrading Statement
Beazley PLCQ1 Results
CMO Group PLCFull Year Results
Monday 15 May 
CentralNic Group PLCFull Year Results
Cerillion PLCHalf Year Results
Currys PLCTrading Statement
Diploma PLCHalf Year Results
Equals Group PLCTrading Statement
Finsbury Growth & Income Trust PLCHalf Year Results
Instem PLCFull Year Results
JPMorgan Multi-Asset Growth & Income PLCFull Year Results
Westminster Group PLCFull Year Results
Tuesday 16 May 
Angling Direct PLCFull Year Results
boohoo Group PLCFull Year Results
Britvic PLCHalf Year Results
Burford Capital LtdFull Year Results
Cornerstone FS PLCFull Year Results
DCC PLCFull Year Results
Essentra PLCTrading Statement
Greggs PLCTrading Statement
Hyve Group PLCHalf Year Results
Imperial Brands PLCHalf Year Results
Land Securities Group PLCFull Year Results
Likewise Group PLCFull Year Results
Marston's PLCHalf Year Results
Renew Holdings PLCHalf Year Results
Smartspace Software PLCFull Year Results
Vodafone Group PLCFull Year Results
Zytronic PLCHalf Year Results
Wednesday 17 May 
Auction Technology Group PLCHalf Year Results
Bank of Georgia Group PLCQ1 Results
British Land Co PLCFull Year Results
Experian PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Keller Group PLCTrading Statement
Ninety One PLC and LtdFull Year Results
Redx Pharma PLCHalf Year Results
Sage Group PLCHalf Year Results
Scottish Mortgage Investment Trust PLCFull Year Results
TP ICAP Group PLCQ1 Results
Watches of Switzerland Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2023 18:05

TRADING UPDATES: Redx confirms Jounce deal lapses, Tirupati seals deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 14:34

Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer

(Alliance News) - Redx Pharma PLC on Monday noted that Jounce Therapeutics Inc, which it was close to buying, was bought by Concentra Biosciences LLC for a higher price.

Read more
27 Mar 2023 14:16

Jounce agrees Concentra Bioscences takeover, ditches Redx Pharma

(Sharecast News) - Jounce Therapeutics said on Monday that it was ditching a planned merger with AIM-listed Redx Pharma, opting instead to be bought by Concentra Bioscences.

Read more
8 Mar 2023 12:07

LONDON MARKET MIDDAY: Stocks down, pound below USD1.19 on US rate view

(Alliance News) - Stock prices in London were lower at midday on Wednesday, with investors still reeling from surprisingly hawkish comments by US Federal Reserve Chair Jerome Powell on Tuesday.

Read more
8 Mar 2023 11:52

Redx Pharma shares slide on RXC004 monotherapy blow

(Alliance News) - Redx Pharma PLC on Wednesday said first results of its phase 2 programme indicate were not sufficient enough to support the development of its RXC004 treatment as a monotherapy.

Read more
8 Mar 2023 10:42

AIM WINNERS & LOSERS: Redx drops on disappointing cancer drug results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Mar 2023 15:44

UK shareholder meetings calendar - next 7 days

Wednesday 8 March 
Amigo Holdings PLCGM re the company's capital position
boohoo Group PLCGM re adoption of the Growth Plan
Creo Medical Group PLCGM re open offer shares
Globalworth Real Estate Investments LtdEGM re grant options and script dividends
Henderson Opportunities Trust PLCAGM
Jersey Electricity PLCAGM
Thursday 9 March 
CT Capital & Income Investment Trust PLCAGM
Shoe Zone PLCAGM
WAG Payment Solutions PLCGM re proposed acquisition of Inelo
Friday 10 March 
Atrato Onsite Energy PLCAGM
Malin Corp PLCAGM
Mineral & Financial Investments LtdAGM
Monday 13 March 
BlackRock Energy & Resources Income Trust PLCAGM
Hercules Site Services PLCAGM
Hummingbird Resources PLCGM re strategic investment and placement
Ironveld PLCGM re second placing shares on AIM
Tuesday 14 March 
Georgia Capital PLCGM re company's transfer from Premium to Standard listing
MTI Wireless Edge LtdAGM
Redx Pharma PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
23 Feb 2023 10:24

Redx Pharma and Jounce Therapeutics agree transatlantic merger

(Alliance News) - Redx Pharma PLC and Jounce Therapeutics Inc on Thursday said they have agreed to an all-share merger that will create a USD425 million company focused on the treatment of cancer and fibrotic diseases.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
9 Feb 2023 12:25

IN BRIEF: Redx Pharma makes progress on fibrosis candidate study

Redx Pharma PLC - Alderley Edge, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Updates on its lead fibrosis candidate, RXC007, which is currently being assessed in a phase 2a study. Says regulatory and ethics approvals for the 28-day and 12-week cohorts of the study have been received in five countries. Adds recruitment is progressing at a number of study sites, but says enrolment in the US 12-week cohort has not begun due to a partial US Food & Drug Adminstration hold, pending a data readout from an ongoing non-clinical programme. The requested data is expected later this year. US enrolment in the 28-day cohort is unaffected.

Read more
20 Dec 2022 14:29

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 Dec 2022 21:22

TRADING UPDATES: Uniphar takeover fails; Pearson notes redemption end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.